Advancing product development and use of monoclonal antibodies for infectious disease in low and middle income countries (LMICs)’
Wellcome Trust
World Health Organization
The project supports activities in the Immunization, Vaccines and biologicalsdepartment of the WHO that aim to advance the product development and use ofmonoclonal antibodies (mAbs) for infectious diseases, with a focus on meeting theneeds of Low and Middle Income Countries (LMICs). Three specific activities will becarried out. First, a stakeholder consultation on monoclonal antibody technologies willbe held to discuss which would best support affordability and accessibility in LMICs.Second, an application to establish rabies mAbs on the WHO model list of essentialmedicines (EML) would set the precedent for inclusion of additional infectious diseasesmAbs in the future. Thirdly, an assessment of diphtheria immunoglobulin supply andpotential demand for mAb-based products will be carried out which could serve as amethodology to be used to assess other mAb based products.”
No Research Activity assigned